Na Hong
Overview
Explore the profile of Na Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ge H, Gao D, Zhang S, Liu C, Chen L, Song Y, et al.
ACS Appl Mater Interfaces
. 2024 Nov;
16(49):68144-68156.
PMID: 39582261
Smart electromagnetic interference (EMI) shielding materials with adjustable shielding efficiency (SE) hold immense importance in the field of wearable and switchable EMI shielding. However, existing materials often suffer from a...
2.
Hong N, Liu W, Zhang J, Qian K, Liu J, Ye X, et al.
World J Gastrointest Surg
. 2024 Sep;
16(8):2494-2502.
PMID: 39220067
Background: Perianal fistulas pose dual challenges to Crohn's disease (CD) patients. Low patient compliance due to the complexity of existing examination methods plagues the treatment and follow-up management of perianal...
3.
Li Y, Peng X, Li J, Zuo X, Peng S, Pei D, et al.
J Am Med Inform Assoc
. 2024 Aug;
31(11):2622-2631.
PMID: 39208311
Objective: In acupuncture therapy, the accurate location of acupoints is essential for its effectiveness. The advanced language understanding capabilities of large language models (LLMs) like Generative Pre-trained Transformers (GPTs) and...
4.
Hong N, Wang B, Zhou H, Wu Z, Fang H, Song G, et al.
World J Gastrointest Surg
. 2024 Aug;
16(7):2329-2336.
PMID: 39087117
Background: Programmed cell death 1 (PD-1) inhibitors are immune checkpoint inhibitors (ICI) that have demonstrated significant efficacy in treating various advanced malignant tumors. While most patients tolerate treatment well, several...
5.
Lei H, Li X, Ma W, Hong N, Liu C, Zhou W, et al.
Cancer Innov
. 2023 Dec;
1(2):135-145.
PMID: 38090651
Background: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis. Predicting overall survival using clinical data would benefit cancer patients by allowing providers to design an...
6.
Zhang Y, Hong N, Huang S, Wu J, Gao J, Xu Z, et al.
Cancer Innov
. 2023 Dec;
1(2):124-134.
PMID: 38090650
Background: Kidney cancer originates from the urinary tubule epithelial system of the renal parenchyma, accounting for 20% of all urinary system tumors. Approximately 70% of cases are localized at diagnosis,...
7.
Hong N, Sun G, Zuo X, Chen M, Liu L, Wang J, et al.
Cancer Innov
. 2023 Dec;
1(1):80-91.
PMID: 38089452
Cancer informatics has significantly progressed in the big data era. We summarize the application of informatics approaches to the cancer domain from both the informatics perspective (e.g., data management and...
8.
Zhou X, Ma X, Gao S, Ma Y, Gao J, Jiang H, et al.
BMC Med Inform Decis Mak
. 2023 Sep;
21(Suppl 9):384.
PMID: 37715170
Background: With the global spread of COVID-19, detecting high-risk countries/regions timely and dynamically is essential; therefore, we sought to develop automatic, quantitative and scalable analysis methods to observe and estimate...
9.
Liu J, Fang H, Hong N, Lv C, Zhu Q, Feng Y, et al.
Microbiol Spectr
. 2023 May;
11(3):e0145723.
PMID: 37199618
Patients with ulcerative colitis (UC) have low response rates to anti-integrin medications, necessitating the identification of noninvasive biomarkers for predicting remission to anti-integrin therapy. In this study, patients with moderate...
10.
Zhou S, Jv D, Meng X, Zhang J, Liu C, Wu Z, et al.
Ann Med
. 2022 Dec;
55(1):215-223.
PMID: 36576390
Background And Aims: Currently, there are still no definitive consensus in the treatment of intrahepatic cholangiocarcinoma (iCCA). This study aimed to build a clinical decision support tool based on machine...